Keros Therapeutics (KROS)
(Delayed Data from NSDQ)
$14.32 USD
0.00 (0.00%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $14.24 -0.08 (-0.56%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Fundamental Charts
About Market Cap
As of the previous market close, Keros Therapeutics, Inc. has a market cap of $581.61M, which represents its share price of $14.32 multiplied by its outstanding shares number of 40.62M. As a small-cap company, KROS's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
KROS 14.32 0.00(0.00%)
Will KROS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KROS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KROS
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
KROS: What are Zacks experts saying now?
Zacks Private Portfolio Services
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Other News for KROS
ClearBridge Small Cap Strategy Q2 2025 Commentary
Noteworthy Friday Option Activity: KROS, TEAM, BYON
Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
Major Shareholder Sells Off Keros Therapeutics Stock!
McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls